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Abstract
We have shown that a specific pyrrole-imidazole polyamide-DNA alkylator (chlorambucil)
conjugate, 1R-Chl, alters the growth characteristics of various cancer cell lines in culture, and
causes these cells to arrest in the G2/M stage of the cell cycle, without apparent cytotoxicity. This
molecule has also shown efficacy in several mouse xenograft models, preventing tumor growth.
Previous microarray studies have suggested that members of the histone H4 gene family, H4c and
H4j/k, are the primary targets of this molecule, leading to reduced histone mRNA synthesis and
growth arrest in cancer cells. In the present study, we examine the effects of 1R-Chl on
transcription of other members of the H4 gene family, with the result that mRNA transcription of
most genomic copies of H4 are down-regulated by 1R-Chl in a human pancreatic cancer cell line
(MIA PaCa-2), but not in a cell line of non-cancerous origin (HEK293 cells). The basis for this
differential effect is likely an open chromatin conformation within the H4 genes in cancer cells.
Chromatin immunoprecipitation experiments show increased histone acetylation on the histone H4
genes in cancer cells, compared to HEK293 cells, explaining the differential activity of this
molecule in cancer versus non-cancer cells.
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Small molecules or antibodies that target enzymes and receptors that are over expressed or
mutated in malignant cells have reshaped modern cancer therapy 1–5. However, DNA
alkylating agents remain among the most common drugs for treatment of human cancer 6, 7.
Novel agents coupling DNA minor groove binders with alkylators have been introduced;
however, due to limited DNA sequence selectivity of these agents, myelotoxicity is often the
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dose-limiting toxicity of these compounds 8–10. New generations of sequence-selective
DNA alkylating agents, based on the conjugation of established DNA alkylators such as
chlorambucil (Chl) 11, 12 or CC-1065/CBI derivatives 13–16 to DNA selective pyrrole-
imidazole (Py-Im) polyamides, have been developed with the aim of reducing such toxicity
by limiting the number of DNA sites targeted in cells. Py-Im polyamides are a class of
synthetic molecules that can be designed to recognize a wide repertoire of DNA sequences
with remarkable affinity and selectivity 17, 18. The polyamide-alkylator conjugates react
covalently with DNA at the specific polyamide binding-site in the genome and inhibit
transcription by stalling RNA polymerase during elongation 19.
Recently, an α-diaminobutyric acid-linked hairpin polyamide-Chl conjugate (1R-Chl, Fig.
1a) has been shown to bind and alkylate its cognate DNA sequence, both in vitro and in the
cell nucleus, and to discriminate between match and single base mismatch
sequences 12, 20, 21. Previous studies have shown that 1R-Chl down regulates expression of
histone H4 mRNA in various cancer cell lines, resulting in cell cycle arrest and a loss of cell
proliferation and tumorigenicity in mouse xenograft models 20, 22. The human genome
encodes 14 genes coding for histone H4 protein, with each gene encoding exactly the same
amino acid sequence, but with silent variations in DNA sequence. Microarray analysis
pointed to the selective down-regulation of H4 family member H4c, and to some extent H4j/
k expression, by 1R-Chl but not other H4 genes 20, 22. By contrast, in the non-cancerous
human embryonic kidney cell line 293 (HEK293), H4c transcript levels were not affected
after treatment with 1R-Chl, and no cycle arrest was noted 20, 23. Since each member of the
H4 gene family harbors potential binding sites for 1R-Chl within their coding region (5’-
WGGWGW-3’, where W = A or T 12, 20), it was unexpected that only H4c and H4j/k
expression would be affected. Moreover, 1R-Chl treatment of human SW620 colon
carcinoma cells lead to a reduction in total histone H4 protein levels 20. These observations
prompted us to examine whether 1R-Chl targets other members of the H4 gene family. We
also explore the basis for the differential effect of this compound on cells of cancer versus
non-cancer origin.
We chose to investigate the effect of 1R-Chl on mRNA levels for each member of the H4
gene family in both a cancer cell line and in a human cell line of non-cancer origin using
quantitative RT-PCR. For our experiments, we chose the human pancreatic cancer cell line
MIA PaCa-2, as previous studies showed that this cell line was highly sensitive to 1R-Chl
treatment, in terms of down-regulation of H4c gene expression and blocking proliferation 23.
As a control cell line, we again chose HEK293 cells, where 1R-Chl was without effect on
H4c gene expression or cell cycle arrest over the concentration range tested previously 23.
This cell line was immortalized by adenovirus-5 infection, but is not of cancer origin. We
first sought to quantify the difference in sensitivity of these two cell lines to 1R-Chl
treatment by monitoring cell growth using the MTS assay (Fig. 1b). By comparing the
concentration of compound required for 50% reduction in cell number (~16 nM for MIA
PaCa-2 cells, compared to ~400 nM for HEK293 cells), the data clearly show that MIA
PaCa-2 cells are approximately 25-fold more sensitive to 1R-Chl than are HEK293 cells.
One explanation for this difference could be the differential ability of the polyamide-Chl
conjugate to penetrate these two cell types; however, previous studies have shown nuclear
accessibility of Py-Im polyamides in this cell type 24 and nuclear accessibility of polyamide-
chlorambucil conjugates in various cell types 15, 25. We therefore examined the ability of a
fluorescent version of the same polyamide, 1R-bodipy 20, to localize in the nucleus of
HEK293 cells. Supplementary Figure 1b clearly shows nuclear staining of such cells after
incubation in culture media for 16 h with 500 nM 1R-bodipy, thereby eliminating this trivial
possible explanation.
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We next determined the effect of 1R-Chl on histone gene expression in the two cell lines.
We were able to generate primers for 11 of the 14 members of the histone H4 gene family.
Family members “j” and “k” cannot be distinguished do to identical coding sequences, and
we were unable to generate efficient primers for family members “f”, “g” and “i”. Treatment
of MIA PaCa-2 cells with 1R-Chl at 50 nM led to down-regulation of all analyzed H4
mRNAs (Fig. 2a). In contrast, none of the H4 transcripts was reduced in HEK293 cells
treated with 1R-Chl at the five-fold higher concentration of 250 nM (Fig. 2b). While
previous microarray studies have identified H4c and H4k/j as the only H4 genes being down
regulated by 1R-Chl in SW620 colon carcinoma and K562 chronic myelogenous leukemia
cells 20, 22, we find that all H4 genes analyzed are affected by treatment with the polyamide
conjugate in MIA PaCa-2 cells. To address this conundrum, we searched for H4 genes
within the microarray data from Chou et al. 22 and found that the expression of many H4
genes was lower in 1R-Chl treated cells versus untreated cells, but only the data for H4c and
H4j/k reached statistical significance (see www.ncbi.nlm.nih/geo/).
The differential effect of 1R-Chl in the two cell lines analyzed prompted us to hypothesize
that the chromatin structure on the H4 genes in cancer cells may differ from that of non-
cancerous cells, and that a more accessible chromatin in MIA PaCa-2 cells would explain
the far greater sensitivity of this cell line to treatment with the polyamide. Chromatin
immunoprecipitation (ChIP) assays were next used to determine the occupancy of histone
H3 on the H4 genes, as a general measure for nucleosome occupancy. As shown in Figure
3a, on at least half of the H4 genes studied, the occupancy of histone H3 is lower in MIA
PaCa-2 cells compared to HEK293 cells. Histone H3 occupancy on the β-actin gene was
used as recovery standard to insure the reliability of the results. These findings suggest that
some of the histone H4 genes may be depleted of nucleosomes within their coding regions in
MIA PaCa-2 cells compared to HEK293 cells. We next asked whether a difference in
histone acetylation might account for the difference in accessibility of the polyamide to the
histone genes in these two cell types. In this experiment, we used antibody to acetylated
histone H3 in ChIP assays (Fig. 3b), and plotted the ratio of acetylated H3 to total H3 in
each sample to account for differences in total histone occupancy (Fig. 3a) and overall
recovery. The data clearly show that histone H3 on the H4 genes in MIA PaCa-2 cells is
highly acetylated compared to the same genes in HEK293 cells.
Our previous studies established that 1R-Chl blocks cancer cell proliferation through a two-
hit mechanism, whereby down-regulation of histone gene expression leads to a general
opening of the genome and subsequent widespread DNA alkylation, leading to a block in the
G2/M phase of the cell cycle 23. We provided both siRNA and chemical evidence that
targeting members of the histone H4 gene family in cancer cells was the basis for the
observed biological effects 22, 23. Indeed, amongst a library of polyamide-Chl conjugates,
only compounds that target the H4 genes were effective in down-regulation of mRNA levels
and blocking cancer cell proliferation 22. Comparison of the results from Affymetrix
microarray studies in both SW620 colon cancer cells 20 and K562 chronic myelogenous
leukemia cells 22, pointed to the H4c gene, and histone H4 protein, as the key target that
elicits the observed growth effects of 1R-Chl. Down regulation of histone H4 or H3 protein
with cognate siRNAs, followed by treatment with a control polyamide-Chl conjugate, which
by itself was inactive, elicited similar growth inhibition as 1R-Chl 23. Taken together, our
data point to the H4 genes as the target of 1R-Chl responsible for growth inhibition, acting
via the two-hit mechanism discussed above.
The current study sought to resolve two unanswered question raised in the previous work;
namely, whether transcription of other members of the histone H4 family, besides H4c and
H4j/k genes, are affected by 1R-Chl, and the molecular basis for the discrimination between
cells of cancer and non-cancer origin by 1R-Chl. As reported previously 20, 23, 1R-Chl
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shows a clear differential effect on MIA PaCa-2 pancreatic cells versus the human
embryonic kidney cell line HEK293 (Fig. 1b). The present data provide a quantitative
estimate of a ~25-fold greater sensitivity of MIA PaCa-2 cells to 1R-Chl, compared to
HEK293 cells. We also show that mRNA levels of all members of the histone H4 gene
family (for which qRT-PCR primers are available) are affected by 1R-Chl in MIA PaCa-2
cells, but not in HEK293 cells (Fig. 2), thus resolving the paradox that down-regulation of
just a few members of the histone H4 gene family should result in a loss of total histone H4
protein, as mentioned above.
The differential sensitivity of cancer versus non-cancer cells to 1R-Chl prompted us to
examine the chromatin composition of the H4 genes in these cells. We speculated that an
open chromatin conformation on the H4 genes could account for the availability of
polyamide binding sites in cancer cells versus cells of non-cancer origin, such as the
HEK293 cells. Open chromatin could arise from the absence of nucleosomes or histone
postsynthetic modifications that lead to more accessible DNA within the nucleosome.
Indeed, ChIP experiments clearly show a reduction in histone H3 occupancy on some
members of the H4 gene family in MIA PaCa-2 cells compared to HEK293 cells (Fig. 3a),
suggesting lower nucleosome occupancy. But more striking, we find higher levels of histone
acetylation on the H4 genes in MIA PaCa-2 cells compared to HEK293 cells (Fig. 3b).
Histone acetylation is a well-established marker of open chromatin 26 and so it is reasonable
to postulate that this modification and the subsequent change in nucleosome structure
adopted through acetylation might well be the basis for the observed biological effects of
1R-Chl in cells of cancer versus non-cancer origin.
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Figure 1.
(a) Polyamide-Chlorambucil Conjugate Structure. 1R-Chl = ImIm-β-Im-α(R-2,4-
DABAChl)-PyPyPyPy-β-Dp, where Py is pyrrole, Im is imidazole, β is β-alanine, Dp is
dimethylaminopropylamine, and 2,4-DABA is (R)-2,4-diaminobutyric acid with α
describing the amino acid linking the polyamide and Chl describing the chlorambucil
substituent at the 4-amino position. (b) Comparison of the effect of 1R-Chl on the growth of
MIA PaCa-2 and HEK293 cells. Cells were grown for 6 days in the presence of varying
concentrations of 1R-Chl (from 1nm to 1µM) and cell viability at day 6 was measured with
the MTS assay.
Jespersen et al. Page 6
Bioorg Med Chem Lett. Author manuscript; available in PMC 2013 June 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
H4 gene expression in MIA PaCa-2 and HEK293 cells. (a) MIA PaCa-2 cells were either
untreated or treated with 50 nM 1R-Chl for 72 h. Shown are the relative mRNA levels of H4
genes (average and standard deviation of three independent experiments, each quantified in
triplicate). GAPDH transcript level was used as recovery standard and the mRNA level of
the H4A gene in untreated cells was set to 1. *, p < 0.05. **, p < 0.01. ***, p < 0.001. (b)
HEK293 cells were treated as in (a) except for the concentration of the polyamide, which
was 250 nM.
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Figure 3.
(a) Histone H3 occupancy on the indicated H4 genes in MIA PaCa-2 cells and HEK293
cells. Chromatin immunoprecipitation was performed with anti-histone H3 antibodies. DNA
recovery is expressed as relative to the recovery of β-actin coding sequence. Error bars are
S.E.M. of two independent immunoprecipitations, each quantified in triplicate. (b) Ratio of
acetylated histone H3 versus total histone H3 occupancy on the indicated H4 genes in MIA
PaCa-2 cells and HEK293 cells. Chromatin immunoprecipitation was performed with anti-
acetylated histone H3 and anti-histone H3 antibodies. Error bars are S.E.M. of two
independent immunoprecipitations, each quantified in triplicate.
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